Telix Pharmaceuticals
- Country
- 🇦🇺Australia
- Ownership
- -
- Employees
- 234
- Market Cap
- $4.5B
- Introduction
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Telix Pharmaceuticals Faces FDA Setback for Brain Cancer Imaging Agent
Telix Pharmaceuticals' brain cancer imaging agent Pixclara (TLX101-CDx) received a rejection from the FDA, which requested additional clinical evidence before approval.
TLX101 Shows Promising Survival Benefits in Recurrent High-Grade Glioma Patients
Preliminary results from the phase 2 IPAX-Linz study demonstrate TLX101 (131I-iodofalan) achieved a median overall survival of 12.4 months from treatment initiation in recurrent high-grade glioma patients.
Biotech Leadership Shuffle Continues as Industry Navigates Transformation in Q2 2025
Novo Nordisk undergoes significant executive restructuring following the departure of EVP Camilla Sylvest, with rare disease leader Ludovic Helfgott taking over expanded commercial strategy responsibilities.
First Patient Dosed in Pioneering ZOLAR Trial of TLX300-CDx for Advanced Soft Tissue Sarcoma
Telix Pharmaceuticals has dosed the first patient in its Phase 1 ZOLAR trial evaluating TLX300-CDx (89Zr-olaratumab) in patients with advanced soft tissue sarcoma at Melbourne Theranostic Innovation Centre.
FDA Approves Telix Pharmaceuticals' Novel Prostate Cancer Imaging Agent
The U.S. Food and Drug Administration has granted approval for Telix Pharmaceuticals' new drug application for their prostate cancer imaging agent, offering improved diagnostic capabilities for clinicians.
Heidelberg Pharma Reports Promising Clinical Progress with HDP-101 in Multiple Myeloma and Advances HDP-102 into Clinical Trials
Heidelberg Pharma's lead ATAC candidate HDP-101 demonstrated safety and tolerability in cohort 7 at 112.50 µg/kg dose for multiple myeloma, with a patient from cohort 5 maintaining complete remission.
Telix Pharmaceuticals Expands Radiopharmaceutical Portfolio with Strategic FAP-Targeting Acquisition
Telix Pharmaceuticals has completed the acquisition of Fibroblast Activation Protein (FAP)-targeting theranostic candidates from Johannes Gutenberg-Universität Mainz, adding TLX400 to its pipeline for bladder cancer and other solid tumors.
Heidelberg Pharma Secures $20 Million in Amended Royalty Deal with HealthCare Royalty for Renal Cancer Diagnostic
Heidelberg Pharma and HealthCare Royalty have amended their royalty financing agreement, providing an immediate $20 million payment to Heidelberg while restructuring future milestone payments.
Telix Pharmaceuticals to Present Advanced Prostate and Kidney Cancer Therapies at ASCO GU 2025
Telix Pharmaceuticals will showcase four presentations at ASCO GU 2025, including preliminary data from the CUPID study demonstrating proof-of-concept for their alpha therapy candidate in prostate cancer.
Telix's Illuccix Receives Approvals in Europe and Denmark for Prostate Cancer Imaging
Telix Pharmaceuticals' Illuccix receives European marketing authorization for prostate cancer imaging, following a positive decision via decentralized procedure.